20 material Form 8-K filings that 19 companies we cover made with the SEC in September 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On September 20, 2023, the board of PIMCO Energy and Tactical Credit Opportunities Fund approved renaming it PIMCO Dynamic Income Strategy Fund with NYSE ticker PDX, changing its investment objectives and strategies, and rescinding its policy to invest at least 80% of net assets in energy-linked and credit-linked investments. For shareholders, the management fee paid to PIMCO will fall from 1.35% to 1.25% of average daily total managed assets, effective December 1, 2023, while the other changes take effect November 21, 2023. The fund will give shareholders 60 days' written notice of the rescission of the 80% Policy.
Board approved the name change and NYSE ticker change to PDX on September 20, 2023
Annual management fee rate to PIMCO cut 0.10%, from 1.35% to 1.25% of average daily total managed assets, effective December 1, 2023
Investment objectives, strategies and the 80% Policy rescission take effect November 21, 2023, with 60 days' written notice to shareholders
Dan Ivascyn, Alfred Murata and Giang Bui added to the portfolio management team
Snap-on entered into a five-year, $900 million multi-currency revolving credit facility maturing September 12, 2028, which replaces its previous $800 million facility set to expire September 16, 2024. As of September 12, 2023, no amounts were outstanding under either facility. The filing describes the terms but does not report any borrowing or change in reported financial results.
New facility: $900 million, five years, terminates September 12, 2028
Accordion feature may increase maximum commitment by up to $450 million with lender approval
Previous facility: $800 million, set to terminate September 16, 2024; no amounts outstanding under either facility
Borrowing spread of 58 to 102.5 basis points over SOFR-based rates, with facility fees of 4.5 to 10 basis points
Deloitte & Touche LLP resigned as the Fund's independent auditor on September 6, 2023, citing an anticipated independence issue tied to a pending transaction between Tekla Capital Management LLC and abrdn Inc. The Board approved KPMG LLP as the Fund's auditor for the fiscal year ending September 30, 2023, on September 7, 2023. Shareholders should note the change comes from a transaction involving the Fund's adviser, though the filing reports no disagreements or reportable events with Deloitte.
Deloitte & Touche resigned September 6, 2023, due to an anticipated independence issue linked to the pending Tekla Capital Management and abrdn Inc. transaction
Audit Committee approved the resignation September 7, 2023; the Board approved KPMG LLP the same day for fiscal year ending September 30, 2023
Deloitte's reports for fiscal years ended September 30, 2022 and 2021 contained no adverse opinion, disclaimer, or qualification
No disagreements or reportable events with Deloitte were reported for those years or the interim period through September 6, 2023
Deloitte & Touche LLP resigned as independent auditor of the Tekla Healthcare Opportunities Fund on September 6, 2023, citing an anticipated independence issue tied to a pending transaction between Tekla Capital Management and abrdn Inc. The Board approved the engagement of KPMG LLP on September 7, 2023 for the fiscal year ending September 30, 2023. The filing states that Deloitte's prior reports contained no adverse opinion or disclaimer and that there were no disagreements or reportable events.
Deloitte & Touche LLP resigned on September 6, 2023, due to an anticipated independence issue
Audit Committee approved Deloitte's resignation on September 7, 2023
KPMG LLP engaged as independent registered public accounting firm for fiscal year ending September 30, 2023
Deloitte's letter to the SEC, dated September 12, 2023, is filed as Exhibit 16.1
Deloitte & Touche resigned as the independent auditor of Tekla Life Sciences Investors on September 6, 2023, citing an anticipated independence issue tied to a pending transaction between Tekla Capital Management LLC and abrdn Inc. The fund's board approved KPMG LLP as its auditor on September 7, 2023, for the fiscal year ending September 30, 2023, and the filing reports no disagreements or reportable events with Deloitte.
Deloitte resigned on September 6, 2023, due to an anticipated independence issue linked to a pending Tekla Capital Management LLC and abrdn Inc. transaction.
The Audit Committee approved the resignation on September 7, 2023, and the board approved KPMG LLP the same day.
Deloitte's reports for the fiscal years ended September 30, 2022 and 2021 contained no adverse or disclaimer opinion and were not qualified or modified.
No disagreements or reportable events with Deloitte occurred in the two most recent fiscal years or the interim period through September 6, 2023.
Deloitte & Touche LLP resigned on September 6, 2023 as independent auditor of the Tekla Healthcare Investors fund, citing an anticipated independence issue tied to a pending transaction between Tekla Capital Management and abrdn Inc. The fund's Board approved KPMG LLP as the new auditor on September 7, 2023, for the fiscal year ending September 30, 2023. The filing reports no adverse opinions, disagreements or reportable events with Deloitte.
Deloitte & Touche resigned on September 6, 2023, due to an anticipated independence issue linked to a pending Tekla Capital Management and abrdn Inc. transaction.
The Audit Committee approved the resignation on September 7, 2023.
KPMG LLP was engaged on September 7, 2023 for the fiscal year ending September 30, 2023.
Deloitte's prior reports for fiscal 2022 and 2021 contained no adverse opinion, disclaimer or qualification, and the filing reports no disagreements or reportable events.
National Beverage reported fiscal first-quarter results for the period ended July 29, 2023, with net sales rising to a record $324 million and net income reaching $49.6 million, up from $35.5 million a year earlier. Management said margins improved on price increases and easing raw material costs, despite a slight volume decrease, and that the quarter has historically been a preview of the full fiscal year.
Net sales increased to $324 million, a record, from $318 million in the prior-year quarter.
Operating profit rose 36% to $63 million; diluted EPS rose 39% to $0.53 from $0.38.
Cash generated by operations increased $30 million to $70 million.
Management cited a slight volume decrease and a seventh consecutive quarterly increase in gross profit per case.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.